Ladies and gentlemen, thank you for standing by. Welcome to Aptar's 2023 Second Quarter Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct a question-and-answer session. Introducing today's conference call is Ms. Mary Skafidas, Senior Vice President, Investor Relations and Communications. Please go ahead.

Thank you. Hello, everyone, and thanks for being with us today. Joining me on today's call are Stephan Tanda, President and CEO; and Bob Kuhn, Executive Vice President and CFO. Our press release and accompanying slide deck have been posted on our website. If you are following along on our website, you can advance the slides by hovering over the presentation screen and clicking on the arrows on the right and left. As always, we will post a replay of this call on our website. Today, this call includes some forward-looking statements. Please refer to our SEC filings to review factors that could cause actual results to differ materially from what we are discussing today. I would now like to turn the conference call over to Stephan.

Thank you, Mary, and good morning, everyone. We appreciate you joining us on the call today. I will begin my remarks by highlighting our results for the second quarter. Later in the call, Bob Kuhn, our CFO, will provide additional details. Starting on Slide 3, for the second quarter, I'm pleased to report that Aptar achieved core sales growth of 4% and delivered double-digit adjusted EPS growth with Q2 landing at $1.23 per share due to the continued strong demand for our pharma proprietary dosing and dispensing systems, as well as our fragrance dispensing technologies. We guided our adjusted earnings per share for the second quarter to be in the range of $1.11 to $1.19. Our adjusted EPS result includes a $0.04 impact from start-up costs related to our injectables expansion program and the rollout of a new enterprise resource planning or ERP system. Our Pharma segment had a very strong first half of the year. In Q2, the robust demand for our proprietary drug delivery systems once again grew across the majority of end-use categories, including nasal decongestion, saline rinses, eye care and cold and cough as well as allergic rhinitis, emergency medicine, asthma and COPD therapies. Our growth in these categories was largely in line with market demand, except for emergency medicine. Revenue from our proprietary drug delivery systems represents about 26% of total company revenue for Aptar in 2022 and is our most profitable area due to our institutional know-how and experience navigating the stringent regulatory requirements in the industry. Over the course of the first half of 2023, more than 85 products and medications using our proprietary drug delivery systems were launched globally. These launches will help us continue to deliver consistent growth well into the future. Today, more than half of all drugs being developed…

Thank you, Stephan, and good morning, everyone. Starting on Slide 7, I would like to summarize the quarter. Our reported sales increased 6%. When we neutralize for currencies and acquisitions, our core sales grew 4%, primarily due to strong demand for proprietary drug delivery systems across the majority of the application fields, including allergic rhinitis, emergency medicine, asthma, COPD, nasal decongestants, saline rinses, cough and cold as well as eye care. Additionally, we saw continued strong demand for our dispensing technologies for both prestige and mass fragrance. As shown on Slide 8, we reported second quarter adjusted earnings per share of $1.23. This represents a 26% increase over prior year adjusted EPS. We achieved adjusted EBITDA of $181 million, which was an increase of 13% from the prior year second quarter. Turning to some of the details by segment for the quarter. Our Pharma segment's core sales increased 13%. Approximately 11% of the continued growth came from increased volumes, especially for our proprietary drug delivery systems. Looking at sales in the Pharma segment by market, prescription core sales increased 23%, primarily due to continued strong demand for dosing and dispensing technologies for allergic rhinitis, emergency medicine, asthma and COPD therapies. Consumer Healthcare core sales increased 19% on healthy demand for nasal decongestants, saline rinses, eye care and cough and cold applications. Core sales for our elastomer solutions for the injectables market increased 1%. While demand for our elastomeric components was strong, shipping days were impacted by an ongoing ERP system migration. The main issues for this implementation have been resolved and we don't expect this impact to repeat in the second half of the year. Turning to our Active Materials Science Solutions, core sales decreased 13% due to softening in demand for probiotics after a period of rapid growth and…

Thanks Bob. In closing, we are energized for the future as many of the measures we have taken over the past years progressively come to fruition. The first half of the year is off to a strong start with solid demand continuing into Q3. The pipeline for our pharma proprietary drug delivery systems continues to build. We are excited about the new opportunities that our expanded injectable capabilities will bring as they come online through the end of 2024. Demand for our last America components is increasing, keeping pace with the fast-growing biologics markets we serve. The Beauty segment continues to perform well in Europe, which represents more than half of our revenue driven by global beauty companies based in Europe, with Latin America also improving very nicely and China recovering, albeit more gradually. We are one of the global leaders in fragrance dispensing and have introduced new technologies that our customers are excited about. And as a result, fragrance has grown double digits in the first six months of the year, and our order book looks strong heading into the third quarter. Equally important, the team has done an excellent job in focusing increasingly on reducing costs while growing the top line. This determined effort to increase our operating leverage and drive productivity is very much continuing. Before opening up the call, I wanted to be sure to recognize and thank two long-serving directors who have decided in recent months to retire from their service on our Board, Andreas Kramvis and Maritza Gomez Montiel. Both have made tremendous contributions to Aptar over their many years of service. Maritza joined our Board in 2015 and served as the Head of our Audit Committee for most of her tenure. Andreas was a member of the Board since 2014, and we benefited from his extensive global industrial operating experience. Also on behalf of my fellow directors, I want to express our thanks to both Maritza and Andreas for the guidance, support and wisdom over the years. With that, I now would like to open the call up for your questions.

[Operator Instructions] We have the first question from Ghansham Panjabi from Baird.

I guess first off, Stephan, maybe you could just touch on what drove the acceleration in pharma core sales in 2Q. I think it was up 7% in the first quarter, up 13% in the second. You mentioned Narcan, et cetera, and lumpiness associated with that but just help us bridge the acceleration between the two quarters.

Sure. I guess, primarily, Ghansham, the -- it is that the Injectable business was delivering at a much higher rate being up more than 50% versus the first quarter, while the sales level for the proprietary dispensing device business maintains at a strong level. And of course, the comparison to prior year also plays a role, but the main acceleration is the injectable business.

Got it. And then as it relates to the strength that you're calling out in fragrance and prestige et cetera, where is the business relative to the pre-COVID baseline? There's just so much noise between 2019 and now. Just curious as to where we are relative to the previous baseline from 2019.

Sure. Ghansham, I can take that. We're above 2019 levels in terms of both units and dollars. So we're back above the pre-COVID levels.

Thank you. We now have George Staphos of Bank of America. Please go ahead.

My two questions are on pharma. I guess, first of all, can you touch on why you needed to raise the headwind guidance, if you will, by $0.01 or so the next couple of quarters for the ERP implementation. And relatedly, what gives you confidence that it's behind you by 2024. And then on the pipeline and volume standpoint for pharma, what do you want us to take away in terms of how GLP-1 drugs and for that matter, emergency medicine pipeline filling will mean for your volumes and how we should model for that over coming quarters?

Sure. So -- what's the first question?

The first question, I can handle the $0.01 headwind. It actually is not the ERP, George. It's really more the ongoing validation of the new capacity expansion. We've added an additional $0.01, primarily due to the additional labor that we've got as the business stabilizes through the ERP. We have every intention of reducing that as the year goes on. But it's mostly an increase in the labor side, but primarily making sure that the validation goes as expected.

Let me just add. I know that this pharma capacity addition world is frustrating if you live in the industrial world. But basically, you build the plant, then you staff it, you make products and then you wait because the products go to the customer, they need to be validated. Everything needs to be checked out and the year later then you actually have ongoing business. So, those of you who remember when we first started up Congress, it took 18 months for the validation. Now this $180 million program for injectables is in phases, so we can validate the phases as we go along. But all of this add cost next to the labor, you have a product that you essentially throw away. And that's just the nature of the pharma business. So it's not like in industrial side, you built the plant, you put the machines in and you're off to the races. It just takes an extra time. And given the rough ERP starting in the first quarter, we just want to be sure that we have the right support as we ramp up those plans. Now on your second question, look, we're not updating our ranges. Our guidance range is the long-term target. If we do that, that would be at the Capital Markets Day. But clearly, what we want to signal is, we feel good about the pipeline, we feel increasingly good about the pipeline. We are in some capacity on all the three major brands that are out there, both the semaglutide and the tirzepatide. And if we had weak volumes in injectables, it's due to the ERP system, not to market demand. And so whatever we lost, if you want, in terms of vaccine -- less vaccine business was easily replaced with additional…

Thank you. We now have Daniel Rizzo of Jefferies. Please go ahead.

Just one question. So you mentioned it takes 5 to 12 years sometimes to get a drug to market for the small and midsized companies. I was wondering, when you guys get involved in the process? Is it from the beginning that you have to be there? Is the pipeline that long? Or is it later, I mean, closer towards launch?

No, we are in there for the duration. That's the strength we bring to this industry. To give you two examples, in Narcan, there was an existing device, we had a Unidose device. Naloxone was the existing molecule. We worked with a small company at the time, that took five years to take an existing molecule, an existing device and get this new indication or administration approved. Another example is Spravato, J&J, that's a 12-year program. Existing molecule, esketamine has been well known and documented, was a new device by dose. It took 12 years. Now in that context, it's important why we have these service businesses and why we strengthened the service businesses. Because we, one, have the expertise that we can provide, but we can also derive revenues. So we bill fee for service. We bill for milestone payments, sometimes renegotiate royalties. So in that pipeline period, we make also descent money. Of course, we make much more money than when the devices are selling. But it is important because once the development is concluded and approved, our device is in the drug master file and that sets it up for a very, very long runway.

And then is -- seasonally speaking, with cough and cold, I assume the third quarter will be -- historically speaking, is the strongest and that there's some lumpiness there as well so that we'll see a surge and then there could be a cooling after that.

Yes. I mean, in our outlook, we basically say we look -- the third quarter looks strong, pretty much copy paste from the second quarter. And there's different product mix, but I wouldn't see a particular surge in quarter three here.

Thank you. Your next question comes from Gabe Hadje of Wells Fargo Securities.

Stephan, Bob, good morning. I wanted to ask it very much short term. I apologize in advance short-term nearsighted question, but one of your customers on the injectable side had a weather event. And I was just curious if you guys have any perspective point of view about how that could impact your own operations, but I don't necessarily know how to think about that.

Look, we cannot talk about any particular customers, but not from my Aptar experience, but previous experience, look, if you get a letter, it's all in how you react and how quickly we react. And I mean, all the participants here are highly experienced and you can only rely on them taking the series and reacting with the vengeance. It doesn't happen all the time, but it's all in how you react to it.

Okay. And then I guess, the two facilities that you were consolidating here in North America, I think there are some labor disruptions and things like that, that were sort of hindering profitability. Can you remind us what savings you are expecting to kind of get out of that? Is it sort of in the rearview mirror? And then I guess on the new reporting structure, where would we expect to kind of see that show up? I suspect the Closures. You talked about the 500 basis points of improvement on the margin year-over-year, but just a clarification there.

Yes. I mean it's been now some time, as a reminder for everyone, just as COVID began, we shut down two facilities in Connecticut and absorbed -- we're planning to absorb those activities into our facilities in the Midwest and the East Coast and in Mexico. That was not as well executed as we would like. We've said that before. We lost some share in the process. And part of that challenge was as we then recovery started, we couldn't get the labor and customers were not pleased. That all is behind us. We did close another facility in the Midwest in Q1. Benefit of that, you do indeed see in Closures. So that's part of the margin improvement. And given that our service levels are back to normal and in fact, very competitive and the regionalization of supply chain, we are back on the front in North America. And the third point is, of course, we suffer like everyone else from the almost mysterious destocking in some markets. We see that pretty much having run its course on the food side, but it's still continued in the personal care and home care side.

[Operator Instructions] As we have had no questions registered, I'd like to hand it back to Mr. Tanda for some final remarks.

Thank you. So let's take a step back for a moment. As I mentioned, the management team here is very energized about the future. And that is because a lot of the hard work, many of the measures that we have taken over the past years are now progressively coming to fruition to a point where you can actually see them in our results, whether it is a much stronger and deeper talent bench or teams that we have on the field that is also leading to disciplined execution, whether it is the much more capable, modern and efficient asset base that we have put in place as well as renovated or updated. Whether it is renewed innovation delivery, our innovation centers in Asia, in the U.S. and in Europe, leading to enthusiastic customer engagement and excitement that I mentioned. And last not least, a much more rigorous and systematic cost focus. All of these improvements starting to show and are behind the double-digit EPS growth. If we look back at the first half, of course, we have risk growth in Rx and CHC in our proprietary dispensing devices and injectables is not recovering nicely with good demand picture looking forward. Beauty is growing nicely in Europe and Latin America and recovery in China in both Europe and China are in the profitability target range. SG&A as a percentage of revenue is coming down. And I also want to make the point that the absolute EBITDA growth, if you combine Beauty and Closures is actually more than the EBITDA growth in Pharma for the first half. Of course, Pharma has been held back with the injectable ERP deployment, but a 14% EBITDA growth for Beauty and Closures combined in Q2, also see that these businesses are starting to deliver, as…

Thank you all for joining. Our time on that does conclude today's call. Please have a lovely rest of your day, and you may now disconnect your lines.